Form 4: Director Douglas Michels Receives WST Restricted Stock

West Pharmaceutical Services Director Douglas A. Michels acquired 791 restricted stock units as part of director compensation.

Summary

• Director Douglas A. Michels was granted 791 restricted stock units (RSUs) of West Pharmaceutical Services, Inc. (WST).
• The transaction occurred on May 4, 2026.
• The shares were acquired at a price of $0, representing equity-based compensation.
• Following this transaction, the director's total beneficial ownership increased to 46,495.55 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation, having no material impact on the company's financial outlook.

Positives

• The grant aligns the director's interests with those of shareholders through equity ownership.

Negatives

• None identified; this is a standard compensatory equity grant.

Risks

• None identified; this is a standard regulatory disclosure of director compensation.

Future Outlook

The restricted stock units are scheduled to vest in full on the date of the next annual shareholder meeting and will be distributable under the company's Deferred Compensation Plan for Outside Directors.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of director compensation, which is standard practice for publicly traded companies in the pharmaceutical packaging and delivery systems sector.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is a common governance practice among S&P 500 and mid-cap companies to ensure long-term alignment with shareholder interests.

Stakeholder Impact

• Minimal impact; reflects standard director compensation practices.

Next Steps

• Vesting of the 791 restricted stock units upon the next annual shareholder meeting.

Key Dates

Keywords

West Pharmaceutical Services, WST, Form 4, Insider Trading, Director Compensation, Restricted Stock Units